With an innovative scientific method and research capabilities behind creating an antibody-drug conjugate, Seattle Genetics has proved itself to be an innovative company that is truly dedicated to helping individuals around the world have a new method for killing cancer without putting toxins in the body. Seattle Genetics was founded in 1998 by Clay Siegall, a leader in the science community who has had years of professional experience with development and research. As the President as well as the CEO of this company, Clay Siegall co-founded this company in order to offer individuals a new therapeutic method to treating cancer. This biotechnology company not only specializes in developing innovative scientific discoveries, but also specializes in commercializing each product that is made to the public. As a company that is currently the leader of an antibody-drug conjugate, Dr. Clay Siegall and his employees have received awards and recognition for their excellent work and research within the industry of science.
The antibody-drug conjugate is a treatment for cancer without the harmful effects that can come from radiation or even from chemotherapy. As an ADC, this conjugate is designed to target monoclonal antibodies. In doing this, the ADC delivers cell-killing agents that are designed to target the cancer cells without harming other cells within the body. This innovation leads to a healthier outcome within the body. The use of ACDs has been approved in over 60 countries and has helped millions of individuals with cancer. In collaboration with Takeda Pharmaceutical Company Limited, the two have continuously negotiated with other countries in order to spread this treatment to other countries in need of a cheap solution.
Above all, the main goal of this company is to help people who have suffered from cancer. With a corporate culture, this company has successfully valued integrity, scientific excellence, innovation, and even team work. As the acknowledged leader of the antibody-drug conjugate, this company hopes to expand more into the future. Clay Siegall states that the reason behind his decision to create this product is to offer a new and non-toxic way to treat cancer without ever having to break the bank.